Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Public ClinicalTrials.gov record NCT01620515. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance. Study participants currently on active surveillance will be randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5 mg or 15 mg) followed by active surveillance or to no treatment (continued active surveillance). Blinded efficacy evaluation will be by a second post-treatment prostate biopsy.
Study identification
- NCT ID
- NCT01620515
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 141 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 85 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2012 (Actual)
- Primary completion
- Oct 21, 2015 (Actual)
- Completion
- Oct 21, 2015 (Actual)
- Last update posted
- Mar 10, 2017
2012 – 2015
United States locations
- U.S. sites
- 23
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Tucson | Arizona | 85715 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Atherton | California | 94027 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | La Mesa | California | 91942 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Long Beach | California | 90806 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | San Diego | California | 92120 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Denver | Colorado | 80220 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Englewood | Colorado | 80113 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | New Britain | Connecticut | 06052 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Aventura | Florida | 33180 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Naples | Florida | 34102 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Jeffersonville | Indiana | 47130 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Shreveport | Louisiana | 71106 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Annapolis | Maryland | 21401 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Baltimore | Maryland | 21204 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Las Vegas | Nevada | 89148 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Brick | New Jersey | 08724 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Albuquerque | New Mexico | 87109 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Garden City | New York | 11530 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | New York | New York | 10016 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Myrtle Beach | South Carolina | 29572 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Germantown | Tennessee | 38138 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Carrollton | Texas | 75010 | — |
| For information concerning this clinical site, please contact Nymox at 800-936-9669. | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01620515, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01620515 live on ClinicalTrials.gov.